Category Archives: Prescribing Newsletter

SGLT2 inhibitors – reports of Fournier’s gangrene

The MHRA have provided the following advice arising from reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum)  – a rare but serious and potentially life-threatening infection – in association with use of sodium-glucose co-transporter 2 (SGLT2) inhibitors: if Fournier’s gangrene is suspected, stop the SGLT2 inhibitor and urgently start treatment (including antibiotics and surgical debridement Continue Reading »

Carbimazole – Stronger Advice on Contraception

The MHRA has strengthened advice for healthcare professionals on contraception requirements for women with childbearing potential prescribed carbimazole. The stronger guidance recommends following advice provided in the FSRH statement on contraception for women using known teratogenic drugs or drugs with potential teratogenic effects. The FSRH statement recommends that women at risk should always be advised to use highly Continue Reading »

Yellow Card App – Updated & Improved

The MHRA have updated and improved the Yellow Card App for iOS and Android. The App allows users to: Report suspected side effects to medicines (including vaccines, herbal products and homeopathic remedies) Track new safety information published by the MHRA about medicines Create a watchlist for alerts to medicines of interest to you View numbers of reports received by Continue Reading »

Tapentadol – Risk of Seizures & Serotonin Syndrome

Following an EU-wide review of safety data and spontaneous reports of serious adverse events, European & UK regulators have strengthened warnings about the risks of both seizures and serotonin syndrome associated with the tramadol-like opioid tapentadol. Regulators have provided the following advice for Healthcare Professionals: tapentadol, like all opioid medicines, can induce seizures tapentadol should be prescribed with care Continue Reading »